Substituted 1,5-naphthyridines as endonuclease inhibitors
US9505758B2 · kind B2 · utility
0Cited by
0References
5Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Oct 22, 2015 |
| Grant date | Nov 29, 2016 |
| Priority date | — |
| Expiry date | Oct 22, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a compound having the general formula (V), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof,which are useful in treating, ameliorating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.